Sign in

You're signed outSign in or to get full access.

EB

EKSO BIONICS HOLDINGS, INC. (EKSO)·Q1 2025 Earnings Summary

Executive Summary

  • Q1 2025 revenue fell to $3.38M, down 10% YoY and sequentially from a record Q4, primarily due to softer legacy EksoNR Enterprise Health device sales as IRF and IDN capital budgets tightened; gross margin held ~53.5% on supply chain/service cost savings .
  • Revenue missed S&P Global consensus as limited Street coverage expected ~$4.62M; two-analyst EPS consensus was -1.65*, while reported GAAP EPS was -$0.12 (comparability caution given post-quarter reverse split) [functions.GetEstimates].
  • Management accelerated the Personal Health channel: named NSM exclusive distributor in U.S. CRT (announced post year-end) and added Bionic P&O in O&P; Medicare beneficiary pipeline expanded to >35, up ~37% from early March, with PRIA guiding claim submissions .
  • Operating cash burn improved materially (Q1 -$2.0M vs -$3.5M YoY) and cash rose to $8.1M; company later announced a 1-for-15 reverse split to regain Nasdaq minimum bid compliance, a near-term trading catalyst .

What Went Well and What Went Wrong

  • What Went Well

    • Personal channel traction and distribution build-out: NSM (exclusive in CRT) and first O&P distributor Bionic P&O; CEO: “significantly expanded access to Ekso Indego Personal via potentially transformative partnerships” .
    • Medicare beneficiary pipeline scaling: >35 qualified candidates in pipeline in Q1, +37% vs ~25 discussed on the March call; PRIA engaged to improve claim quality and throughput .
    • Margin resilience and cost control: gross margin ~53.5% aided by supply chain/service cost savings; Ops expected margins to trend higher with volume mix normalization .

  • What Went Wrong

    • Top-line softness: revenue declined to $3.38M on lower legacy EksoNR sales as IRF/IDN capital budgets were temporarily impacted by macro uncertainty; sequential deceleration from record Q4 .
    • Enterprise demand timing: management flagged IDN off-cycle effects and sudden budget pullbacks, plus uncertainty around grant-funded capital purchases—pressuring near-term Enterprise placements .
    • Higher G&A from one-time items: Q1 G&A rose to $2.55M (vs $2.25M YoY) driven by intangible asset impairment and higher legal/audit costs (partly offset by lower discretionary payroll) .

Financial Results

MetricQ3 2024Q4 2024Q1 2025
Revenue ($USD Millions)$4.13 $5.09 $3.38
Gross Profit ($USD Millions)$2.21 $2.71 $1.81
Gross Margin %53.5% 53.0% 53.5%
Sales & Marketing ($USD Millions)$1.76 $1.88 $1.71
R&D ($USD Millions)$0.78 $0.85 $0.99
G&A ($USD Millions)$2.31 $2.22 $2.55
Total OpEx ($USD Millions)$4.85 $4.94 $5.25
Operating Income (Loss) ($USD Millions)$(2.64) $(2.23) $(3.44)
Net Income (Loss) ($USD Millions)$(2.07) $(3.41) $(2.89)
Diluted EPS ($)$(0.10) $(0.14) $(0.12)
Cash & Restricted Cash ($USD Millions)$8.29 $6.49 $8.05

Additional cash flow

  • Net cash used in operations: Q4 2024 $(1.4)M ; Q1 2025 $(2.0)M .

Notes

  • Ekso reports as one operating/reportable segment; management describes Enterprise Health and Personal Health markets for commercial focus but no numerical segment breakout .
  • Other income in Q1 included a $1.34M gain on warrant liability revaluation and $0.63M FX gain (total other income net $0.55M), partially offsetting operating loss .

KPIs and Operational Indicators

KPIQ3 2024Q4 2024Q1 2025
EksoHealth devices sold (units)33 n/an/a
Gross margin ≥ 53% (streak)53.5% 53.0% 53.5%
Medicare Indego Personal beneficiary pipeline (candidates)n/a~25 (as of early March) >35 (+~37% vs Q4 call)

Guidance Changes

No formal quantitative guidance was issued. Management commentary emphasized:

  • 2025 mix: Enterprise expected to remain the “large majority” (~75%–80%) of revenue, with Personal contribution growing through the year .
  • Gross margin: operations expects margins to remain in the low-to-mid 50s and trend higher with volume/mix normalization; Q1 margin was dampened by lower volume and mix (more Europe) .
MetricPeriodPrevious GuidanceCurrent GuidanceChange
RevenueFY2025NoneNo formal guidance; enterprise majority, personal rampingMaintained (no guide)
Gross MarginFY2025NoneExpect sustained low-to-mid 50s; potential improvement with volume/mixMaintained qualitative
OpExFY2025NoneContinued cost discipline; no numeric guideMaintained qualitative
Segment/Channel2025NoneCRT (NSM) and O&P (Bionic P&O) to broaden Personal accessNew qualitative color

Earnings Call Themes & Trends

TopicPrevious Mentions (Q3’24)Previous Mentions (Q4’24)Current Period (Q1’25)Trend
CMS reimbursement & Personal channelInitial CMS reimbursement; multiple claims submitted; program takes time to build Engaged PRIA; built ~25 Medicare candidate backlog; paused Q4 submissions pending process enhancements Pipeline >35 (+~37%); distributors ramping; expect increasing Personal contribution in 2025 Improving execution/pipeline
Distribution build-outExpanding distribution internationally; IDN timing in NA Named NSM exclusive distributor in CRT (U.S.) Added Bionic P&O as first O&P distributor; NSM + Bionic to broaden access Channel expansion
Enterprise demand/IDN budgetsIDN procurement delays; macro uncertainty 2024 off-cycle; renewal cycles expected in 2025 IRF/IDN budgets soft in Q1; some grants uncertain; expect normalization but timing uncertain Mixed; near-term soft
Gross margin sustainability53.5% despite more distribution 53% with supply chain/service savings ~53.5%; expected higher but impacted by lower volume/mix; ops confident in trend Stable to modestly up with scale
Regional trendsEurope strong; APAC growing Europe strength to continue in Q4; APAC growth opportunities Mix impact from Europe noted in Q1 margin commentary Europe remains supportive
AI/technology——Accepted into NVIDIA Connect to build foundation model for human motion (post-quarter PR) New strategic initiative
Capital/ListingCompleted equity raise Sep-24 —Reverse split 1-for-15 effective May 27, 2025 to regain bid compliance Listing compliance action

Management Commentary

  • “Over the past few weeks, we have significantly expanded access to Ekso Indego Personal via potentially transformative partnerships… Both partnerships represent Ekso Bionics’ first entrances into these large and growing markets.” — Scott Davis, CEO .
  • “We do expect solid [Personal] contribution growing quarter-over-quarter… [Enterprise] will represent the large majority of what we do, 75% to 80% of our business.” — Scott Davis, Q&A .
  • “We believe that the claims that are being submitted today are very comprehensive and have a high probability of going through.” — Scott Davis, on PRIA/claims .
  • “We frankly expected margins to be a bit higher in Q1… [impact] driven by lower volume… some of it was mix too… fair contribution from Europe.” — Scott Davis .
  • “Strengthened financial position by improving operating cash burn by 43% combined with $3.8 million in net proceeds from the exercise of warrants.” — Press release highlights .

Q&A Highlights

  • Channel mix and 2025 revenue split: Enterprise still ~75%–80% in 2025; Personal ramping via CRT (NSM) and O&P (Bionic P&O); CRT vs O&P mix uncertain but could approach 50/50 as CRT ramps .
  • Claims process and PRIA impact: Enhanced documentation and process understanding; comprehensive submissions despite lack of definitive CMS/DME MAC criteria; confidence in higher success probabilities .
  • Enterprise budgets: Q1 affected by sudden budget pullbacks and grant uncertainty at IRFs/IDNs; 2025 IDN renewals appear on track, but macro remains a watch item .
  • Margin outlook: Four consecutive quarters ≥~53%; expected to improve with higher volumes and favorable mix; Q1 shortfall vs internal expectations due to lower volumes/mix .
  • Distribution economics: Leveraging distributors reduces internal G&A burden but requires margin to support two-tier model; cost controls and scale expected to preserve margin profile in “high-50s plus” over time .

Estimates Context

MetricPeriodS&P Global ConsensusActualSurprise
Revenue ($USD Millions)Q1 2025$4.62M* (2 ests)$3.38M -$1.25M (~-27.0%)*
Primary EPSQ1 2025-1.65* (2 ests)-$0.12 (GAAP diluted) n/a (scale not fully comparable)*
  • Street coverage remains thin (two estimates). Revenue materially missed consensus; for EPS, S&P’s “Primary EPS” may reflect share adjustments not directly comparable to reported GAAP EPS; S&P did not present an “actual” in our pull. Values retrieved from S&P Global*. [functions.GetEstimates]

Key Takeaways for Investors

  • Near-term: Expect choppy revenue as Enterprise (legacy EksoNR) navigates IDN/IRF budget timing; watch for signs of capital cycle normalization and grant clarity through 2H25 .
  • Personal channel is the 2025 growth lever: NSM (CRT) and Bionic P&O (O&P) should expand access; track submitted/approved Medicare claims and time-to-payment as leading indicators .
  • Margins resilient: Sustained ~53%+ gross margin provides operating leverage potential if volumes recover; mix shift (Europe/Personal) and scale will dictate upside .
  • Cash runway improved but still dependent on execution: Cash rose to $8.1M and burn improved; watch working capital (AR collections as pipeline converts) and operating cash trends .
  • Corporate actions and narrative catalysts: Reverse split to regain Nasdaq bid compliance (technical), and NVIDIA Connect/AI foundation model initiative (strategic) could influence sentiment and optionality .
  • Estimate resets likely on the revenue line post-miss: With only two estimates, consensus may recalibrate lower until Enterprise timing and Personal claims throughput are more visible*. Values retrieved from S&P Global*. [functions.GetEstimates]

Appendix: Additional Relevant Press Releases

  • Bionic P&O appointed first O&P distributor for Indego Personal (Apr 23, 2025) .
  • Q1 results announcement timing (Apr 28, 2025) .
  • NVIDIA Connect acceptance for AI foundation model in rehab (May 15, 2025) .
  • Reverse stock split 1-for-15 effective May 27, 2025 (May 19, 2025) .